This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sterol 14 Alpha-Demethylase Inhibitor development. The report ...

Fate Therapeutics FATE reported a loss of 32 cents ... Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a ...

Cidara Therapeutics' CD388 is aimed at providing universal protection with a single yearly dose for each flu season. See why ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

ATLANTA, May 5, 2025 /PRNewswire/ -- Odylia Therapeutics, a nonprofit (501(c)3) biotechnology company dedicated to advancing treatments for rare diseases, today announced its latest pipeline ...

Palvella Therapeutics (NASDAQ: PVLA) presented its Q1 2025 financial results and corporate update on May 15, 2025, highlighting progress in its rare disease pipeline and strong financial footing.

May 08, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living ...